Founder Elizabeth Holmes admits that direct-to-consumer testing company Theranos’ technology doesn’t work – and wasn’t often used
Michael Schubert |
Much like the rest of the world, pathologists have been watching with fascination as the story of direct-to-consumer testing company Theranos unfolds. From the debut of its revolutionary “Edison machine” technology – purportedly providing instant diagnoses from a single drop of blood – to the discovery that not all was as it seemed, Theranos has been making headlines ever since it first caught the public’s eye in 2013, a decade after its launch. But all that glitters is not diagnostic gold, and in 2015, the Wall Street Journal broke a story announcing that the company’s flagship technology wasn’t being used for most of its tests – and that when it was used, the results might be inaccurate (1).
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine